Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3836 in Multiple Myeloma
NCT07490613Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-3836 in multiple myeloma (MM), sponsored by Hengrui Therapeutics. Primary endpoint: Recommended Phase II Dose at 24 months. Started Jun 2026; status: recruiting.
02
Drugs
SHR-3836
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07490613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490613.